IMMUNOGENETIC FACTORS IN THE PROGNOSIS OF HIV INFECTIONS

HIV 感染预后中的免疫遗传因素

• 批准号: 3142407
• 负责人: MARILYN S POLLACK
• 金额: $ 16.24万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 1989
• 资助国家: 美国
• 起止时间: 1989-09-30 至 1992-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3142407
• 关键词: HIV infections; Kaposi's sarcoma; antibody; antiviral antibody; cell membrane; complement; concanavalin A; gene expression; helper T lymphocyte; histocompatibility antigens; human subject; immunogenetics; mitogens; opportunistic infections; prognosis; ribavirin; sign /symptom; suppressor T lymphocyte

Since infection with the virus causing Acquired Immunodeficiency Syndrome (AIDS), HIV, as detected by the presence of specific antibodies to that virus, occurs in an increasing number of individuals who continue to have no or only very preliminary symptoms of actual clinical manifestations of the infection for prolonged periods, immunogenetic factors may contribute to the ability of different individuals to control virus effects. Many such individuals are being monitored in Houston for the possible development of clinical symptoms and signs and some are being treated in experimental protocols designed to evaluate whether or not certain antiviral agents may prevent the development of clinical symptoms and signs and some are being treated in experimental protocols designed to evaluate whether or not certain antiviral agents may prevent the development of clinical signs and/or increase T4 cell counts. Various studies indicate that some of these antibody positive individuals will develop clinical manifestations of the immunodeficiency syndrome each year. They also suggest that genetic and immunological parameters that may predict which clinical manifestations (i.e., Kaposi's sarcoma vs opportunistic infections) they might develop include histocompatibility type, complement allotype, cell surface phenotype profile, and in vitro immune function responses. The specific purpose of this project will be to collect histocompatibility, complement allotype, cell surface phenotype and immune function data for a large group of individuals with antibodies to HIV and to correlate these genetic/immune response factors to clinical course including responses to various prophylatic drug treatment protocols. Patients at all stages of possible responses to infection will be recruited as long as information is available as to the approximate likely data of initial infection or first appearance of antibody. Approximately 150 patients per year will be recruited for the study. Cell surface phenotype, including percentage of cells with T4 and T8 and dual staining T8-Leu 7, T8-T10, and T8-Dr, and relative immune responses to PHA, con A, pokeweed mitogen and allogeneic cells, will be assessed at least 3 times per year for each patient. Data from clinical studies relating to skin test responses will also be incorporated into the analyses.

由于感染了导致获得性免疫缺陷综合征的病毒 (艾滋病)，艾滋病毒，通过存在对该病毒的特定抗体而检测到 病毒，发生在越来越多的继续患有 没有或只是非常初步的实际临床表现的症状 长期感染，免疫遗传因素可能起作用 不同个体控制病毒影响的能力。许多 这些人正在休斯顿接受监控，以确定可能的 临床症状和体征的发展，一些正在接受治疗 实验方案设计用于评估是否确定 抗病毒药物可能会阻止临床症状的发展和 一些症状和一些正在接受实验方案的治疗，旨在 评估某些抗病毒药物是否可以预防 出现临床体征和/或T4细胞计数增加。五花八门 研究表明，这些抗体阳性的人中的一些人会 发展为免疫缺陷综合征的临床表现 年。他们还表明，遗传和免疫学参数 可以预测哪些临床表现(即卡波西肉瘤与 机会性感染)他们可能发展为组织相容 类型、补体同种异型、细胞表面表型分布和体外 免疫功能反应。 这个项目的具体目的将是收集 组织相容性、补体同种异型、细胞表面表型和 一大群抗体阳性的人的免疫功能数据 并将这些遗传/免疫反应因素与临床联系起来 疗程包括对各种预防性药物治疗的反应 协议。处于感染可能反应的所有阶段的患者将 只要有大致的信息就可以招募 首次感染或首次出现抗体的可能数据。 每年将招募大约150名患者参加这项研究。细胞 表面表型，包括带有T4和T8和Dual的细胞的百分比 T8-Leu7、T8-T10和T8-DR染色及相关免疫反应 PHA、conA、商陆有丝分裂原和同种异体细胞将在 每位患者每年至少服用3次。来自临床研究的数据 与皮肤测试反应相关的信息也将被纳入 分析。